CD105 Expression in Liver Cancer
Author Information
Author(s): Yu Decai, Zhuang Linyuan, Sun Xitai, Chen Jun, Yao Yongzhong, Meng Kui, Ding Yitao
Primary Institution: Nanjing University
Hypothesis
CD105 might be an appropriate targeting for antiangiogenesis therapy in hepatocellular carcinoma (HCC).
Conclusion
CD105 may not be an appropriate targeting for antiangiogenesis therapy in HCC, especially with cirrhosis.
Supporting Evidence
- CD105 was found to be more abundant in non-tumor tissues than in tumor tissues.
- The expression of CD105 mRNA correlated with VEGF165 levels in liver tissues.
- Higher microvessel density (MVD) of CD105 was observed in adjacent non-tumor tissues compared to tumor tissues.
Takeaway
The study looked at a protein called CD105 in liver cancer and found it was more common in healthy tissue than in cancerous tissue, suggesting it might not be a good target for treatment.
Methodology
Liver tissues from 64 HCC patients were analyzed using immunohistochemistry, Western blotting, and real-time PCR.
Potential Biases
Potential bias in the selection of tissue samples and the interpretation of immunohistochemical results.
Limitations
The study did not explore the long-term effects of targeting CD105 in HCC treatment.
Participant Demographics
64 patients (53 males, 11 females; median age 51 years) with hepatocellular carcinoma.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website